Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism

详细信息    查看全文

• 作者：Mana Mitsuguro (1)
  Toshiyuki Sakata (1)
  Akira Okamoto (1)
  Sachika Kameda (1)
  Yoshihiro Kokubo (2)
  Yoshiaki Tsutsumi (3)
  Michitaka Sano (1)
  Toshiyuki Miyata (4)
  
• 关键词：Antithrombin deficiency ; Deep vein thrombosis ; Phenotype ; Risk assessment ; Venous thromboembolism
• 刊名：International Journal of Hematology
• 出版年：2010
• 出版时间：October 2010
• 年：2010
• 卷：92
• 期：3
• 页码：468-473
• 全文大小：214KB
• 参考文献：1. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 1996;87:3531-4.
  2. Perry DJ, Carrell RW. Molecular genetics of human antithrombin deficiency. Hum Mutat. 1996;7:7-2. CrossRef
  3. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 1. Thromb Haemost. 1996;76:651-2.
  4. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516-0.
  5. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, et al. Antithrombin mutation database: 2nd (1997) update For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77:197-11.
  6. Miyata T, Sato Y, Ishikawa J, Okada H, Takeshita S, Sakata T, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res. 2009;124:14-. CrossRef
  7. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-1.
  8. Sanson BJ, Simioni P, Tormene D, Moia M, Friederich PW, Huisman MV, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood. 1999;94:3702-.
  9. Sakata T, Okamoto A, Mannami T, Matsuo H, Miyata T. Protein C and antithrombin deficiency are important risk factors for deep vein thrombosis in Japanese. J Thromb Haemost. 2004;2:528-0. CrossRef
  10. Vossen CY, Walker ID, Svensson P, Souto JC, Scharrer I, Preston FE, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol. 2005;25:1992-. CrossRef
  11. Vossen CY, Conard J, Fontcuberta J, Makris M, VDM FJ, Pabinger I, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost. 2005;3:459-4. CrossRef
  12. Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113:5314-2. CrossRef
  13. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;87:106-2. CrossRef
  14. Wells PS, Blajchman MA, Henderson P, Wells MJ, Demers C, Bourque R, et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol. 1994;45:321-. CrossRef
  15. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost. 1987;58:1094.
  16. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med. 1989;87:34S-S. CrossRef
  17. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med. 1992;116:754-1.
  18. Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci USA. 1984;81:289-3. CrossRef
  19. Okamoto A, Sakata T, Mannami T, Baba S, Katayama Y, Matsuo H, et al. Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita study. J Thromb Haemost. 2003;1:2397-03. CrossRef
  20. Miyata T, Kimura R, Kokubo Y, Sakata T. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol. 2006;83:217-3. CrossRef
  21. Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita study. Stroke. 2009;40:2674-. CrossRef
  22. Kokubo Y, Kamide K, Okamura T, Watanabe M, Higashiyama A, Kawanishi K, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort: the Suita study. Hypertension. 2008;52:652-. CrossRef
  23. Ueyama H, Murakami T, Nishiguchi S, Maeda S, Hashimoto Y, Okajima K, et al. Antithrombin III Kumamoto: identification of a point mutation and genotype analysis of the family. Thromb Haemost. 1990;63:231-.
  24. Shimizu K, Toriyama F, Ogawa F, Katayama I, Okajima K. Recurrent leg ulcers and arterial thrombosis in a 33-year-old homozygous variant of antithrombin. Am J Hematol. 2001;66:285-1. CrossRef
  25. Okajima K, Abe H, Wagatsuma M, Okabe H, Takatsuki K. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin. Am J Hematol. 1995;48:12-. CrossRef
  26. Nagaizumi K, Inaba H, Amano K, Suzuki M, Arai M, Fukutake K. Five novel and four recurrent point mutations in the antithrombin gene causing venous thrombosis. Int J Hematol. 2003;78:79-3. CrossRef
  
• 作者单位：Mana Mitsuguro (1)
  Toshiyuki Sakata (1)
  Akira Okamoto (1)
  Sachika Kameda (1)
  Yoshihiro Kokubo (2)
  Yoshiaki Tsutsumi (3)
  Michitaka Sano (1)
  Toshiyuki Miyata (4)
  
  1. Laboratory of Clinical Chemistry, National Cerebral and Cardiovascular Center, 5-7-1, Fujishirodai, Suita, Osaka, 565-8565, Japan
  2. Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, 5-7-1, Fujishirodai, Suita, Osaka, 565-8565, Japan
  3. Department of Medicine, National Cerebral and Cardiovascular Center, 5-7-1, Fujishirodai, Suita, Osaka, 565-8565, Japan
  4. Research Institute, National Cerebral and Cardiovascular Center, 5-7-1, Fujishirodai, Suita, Osaka, 565-8565, Japan
  

文摘

Inherited antithrombin deficiency, an established risk factor for venous thromboembolism (VTE), can be classified into type I (quantitative deficiency) or type II (qualitative deficiency). In the present study, we assessed the VTE risk associated with the phenotypes of antithrombin deficiency in patients admitted to our hospital. We found that patients with type I deficiency (n?=?21) had more VTE events and earlier onset of VTE than those with type II deficiency (n?=?10). The VTE-free survival analysis showed that the risk for VTE in patients with type I deficiency was sevenfold greater than that in patients with type II deficiency (hazard ratio: 7.3; 95% confidence interval: 1.9-2.2; P?=?0.0009). The prevalence of type I deficiency in the VTE group (5.6%, 6/108) was higher than that in the general population (0.04%, 2/4,517) (odds ratio: 132.8; 95% confidence interval: 26.5-66.1; P?<?0.0001). However, the prevalence of type II deficiency was not different between the VTE group and the general population. Our study indicated that the risk for VTE in patients with type I deficiency was much higher than that in patients with type II deficiency. Thus, simple phenotypic classification of antithrombin deficiency is useful for assessment of VTE risk in Japanese.